A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh

fyodor32768 | 2 points | Jun 16 2020 12:24:16

A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh

Completed study-no results yet.

https://clinicaltrials.gov/ct2/show/NCT04434144

This study was done from May 2nd to June 5th, 2020. The investigators included 181 patients who were tested positive for SARS-CoV-2 infection by RT PCR presented and the sample collected at Chokoria Upazila Health Complex, Cox's Bazar; Bangladesh. The PCR analysis of the collected sample was done at Cox's Bazar Medical College. Each of the participants was examined carefully to find out the details of the disease symptoms, history, comorbid condition, and associated complaints. Patients with severe comorbid conditions like severe Bronchial asthma, COPD exacerbation, severe ischemic heart disease, uncontrolled diabetes mellitus, advanced renal and hepatic disease, carcinoma, hospitalized and Immuno-compromised patients were not included in this study. 42 patients had comorbid conditions (some required hospitalization) that might affect the recovery time; 14 patients were unwilling to participate in the study and 9 participants did not show-up (3 from group A and 6 from group B) for follow up sample collection so these were excluded. Following exclusion 116 patients were included with mild to moderate degree of illness with normal or near-normal chest radiograph and Oxygen Saturation more than 95% were included in this study. All the patients enrolled in the study were treated as an outpatient protocol.

For the study Perouse the participants were divided into two groups as follows:

Group A (n=60): Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days.

Group B (n=56): Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.

Besides the above, symptomatic treatment for fever, headache, cough, myalgia, and other complaints were given accordingly. Participants were advised for self-isolation, proper nutrition, hydration, and a sanitary environment. Treatment outcomes were evaluated on every 2days starting from the 5th day (Asymptomatic patients) or the 2nd non-symptomatic day from the first day of the drug intake by PCR study of nasopharyngeal and throat swab in each group. Regular contacts were maintained to find out the adverse or side effects of the therapy. Informed consent was obtained in every case.

[-] TrumpLyftAlles | 1 points | Jun 16 2020 14:17:12

Thanks for writing it up so nicely.

Why isn't this a LINK? Can we get a link to the trial please?

[-] fyodor32768 | 2 points | Jun 16 2020 16:13:06

I can't seem to get the link into the header-it's in the writeup now.

[-] TrumpLyftAlles | 1 points | Jun 16 2020 18:20:04

Please do the following, then move your nice long post to the new post, then delete this post.

1) Put the link in the clipboard (you can get it from where you posted it in the study description)

2) Click "Submit a new link" in the upper-right corner of the web page, paste the link into the provided place, give reddit a few seconds to present the suggested title, click the thing so the suggested title is used, add (Bangladesh, 2020-06-16, ClinicalTrials) to the title, click the [Submit] button.

That done, anyone clicking the post title will be taken to the trial on ClnicalTrials.gov.

If that's too hard, let me know and I'll do it. I don't want the karma, though, and if you are going to keep posting to the sub, you should do it the way I outline above.

I hope this doesn't seem obnoxious!

Let me know if you have questions.